Demographic data and baseline characteristics of study patients. Plus/minus values are mean ± SD.
| Variables | Secukinumab IV Loading, n = 88 | Secukinumab SC Loading, n = 89 | Placebo, n = 44 |
|---|---|---|---|
| Age, yrs | 53.8 ± 11.81 | 54.5 ± 12.26 | 53.5 ± 9.33 |
| Female, n (%) | 67 (76.1) | 72 (80.9) | 37 (84.1) |
| Race, n (%) | |||
| White | 86 (97.7) | 85 (95.5) | 44 (100) |
| Black | 0 | 2 (2.2) | 0 |
| Other | 2 (2.3) | 2 (2.2) | 0 |
| Body weight, kg | 74.4 ± 15.15 | 76.6 ± 19.15 | 71.3 ± 13.62 |
| Duration of RA, yrs | 7.7 ± 7.91 | 7.6 ± 7.14 | 7.5 ± 7.72 |
| Adjusted swollen 66-joint count† | 14.3 ± 7.39 | 15.0 ± 10.50 | 13.3 ± 5.82 |
| Adjusted tender 68-joint count† | 23.6 ± 12.93 | 23.0 ± 12.37 | 22.2 ± 10.26 |
| DAS28-CRP | 5.6 ± 1.06 | 5.5 ± 0.97 | 5.7 ± 0.82 |
| DAS28-ESR | 6.4 ± 0.97 | 6.4 ± 0.96 | 6.4 ± 0.78 |
| Patient’s global assessment of disease activity, VAS, mm | 60.0 ± 23.27 | 60.8 ± 22.05 | 60.3 ± 16.21 |
| Physician’s global assessment of disease activity, VAS, mm | 62.9 ± 15.15 | 63.5 ± 16.85 | 61.9 ± 14.20 |
| Patient’s assessment of RA pain, VAS, mm | 54.9 ± 23.86 | 59.1 ± 21.23 | 55.9 ± 18.62 |
| hsCRP, mg/l | 11.6 ± 14.26 | 13.7 ± 19.50 | 10.3 ± 9.32 |
| HAQ-DI | 1.5 ± 0.64 | 1.5 ± 0.65 | 1.5 ± 0.61 |
| RF, U/ml | 129.2 ± 124.75 | 142.9 ± 207.48 | 170.3 ± 187.05 |
| RF-positive (≥ 14 U/ml), n (%) | 84 (95.5) | 85 (95.5) | 44 (100) |
| Anti-CCP antibody-positive, n (%) | 77 (87.5) | 71 (79.8) | 35 (79.5) |
↵† If the number of joints for which data were available (e.g., T) was < 66 for the swollen joint assessment or < 68 for the tender joint assessment, the number of swollen or tender joints (e.g., t) was scaled up proportionately (i.e., 66*[t/T] for swollen joint or 68*[t/T] for tender joint). IV: intravenous; SC: subcutaneous; CCP: cyclic citrullinated peptide; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; RF: rheumatoid factor; hsCRP: high-sensitivity CRP; RA: rheumatoid arthritis; VAS: visual analog scale.